Cellular Therapy for Cardiovascular Disease Part 1 - Preclinical Insights

Peter J Psaltis1, Stan Gronthos2, Stephen G Worthley1 and Andrew C.W. Zannettino2 1Cardiovascular Research Centre, Royal Adelaide Hospital; Department of Medicine, University of Adelaide, South Australia, 5000. 2Division of Haematology, Institute of Medical and Veterinary Science; Department of Medicine, University of Adelaide, South Australia, 5000. Abstract Coronary artery disease (CAD) and congestive heart failure (CHF) are leading causes of morbidity and mortality in Western communities and represent a growing economic burden to most health systems. Cell-based therapy represents a novel treatment strategy to treat CAD and CHF. The first part of this two-part review will address the biological properties and functional potential of different cell types that have been trialled in preclinical cardiovascular research. Part two will focus on the clinical application of these cells and will discuss the lessons learnt from clinical trial experience so far.

Abstract licence: CC BY-NC

40 more references, whose wording the paper’s licence keeps private.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.